Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Diclofenac Potassium
Deflox · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| First Deflox®, Then Cataflam DD® | EXPERIMENTAL | Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2. |
| First Cataflam DD®, Then Deflox® | EXPERIMENTAL | Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2. |
| Name | Type | Description |
|---|---|---|
| Deflox® | DRUG | Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions. |
| Cataflam DD® | DRUG | Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions. |
Inclusion Criteria: * Participants who have a body weight within 55-95 kilograms (kg) and body mass index (BMI) within the range 18.0-27.0 kilogram/meter square (kg/m2) (inclusive) * Participant has given written informed consent before any study-related activities are carried out - Participants wi...
Deflox is an investigational small molecule developed by Merck KGaA. It has been studied in a Phase 1 bioequivalence trial in healthy adult volunteers. The specific therapeutic indication for Deflox has not been publicly disclosed.
Deflox is developed by Merck KGaA, which trades under the ticker MKGAF. The company sponsored the clinical trial evaluating Deflox tablets.
Deflox is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA.
Deflox has been evaluated in one completed Phase 1 trial, NCT04132583, titled the Deflox Tablets Bioequivalence (BE) Trial. The trial enrolled 16 healthy adult volunteers in Mexico and used a randomized, controlled design.
Yes, Deflox and Deflox® refer to the same investigational small molecule developed by Merck KGaA. The registered trademark symbol is simply a stylized version of the same drug name used in official documentation.